Table 2. Univariate analysis for the associations between the personal and clinical characteristics and the OS for pCCA patients in the primary training cohort (N = 235).
| Demographic or characteristic factor | HR (95% CI) | P-value |
|---|---|---|
| Age (per year) | 1.02 (1.01-1.03) | 0.016 |
| Sex (Female vs. Male) | 0.99 (0.73-1.34) | 0.940 |
| Tumor size (per cm) | 1.08 (0.95-1.24) | 0.233 |
| Differentiation | ||
| Medium vs. Low | 0.70 (0.45-1.07) | 0.101 |
| High vs. Low | 0.44 (0.19-1.03) | 0.060 |
| Bismuth staging | ||
| II vs. I | 0.90 (0.51-1.61) | 0.730 |
| IIIa vs. I | 1.11 (0.93-1.97) | 0.712 |
| IIIb vs. I | 1.28 (0.75-2.18) | 0.368 |
| Gazzaniga staging | ||
| II vs. I | 1.30 (0.92-1.83) | 0.138 |
| III vs. I | 2.71 (1.70-4.32) | < 0.001 |
| IV vs. I | 2.40 (1.13-5.11) | 0.023 |
| MSKCC T staging | ||
| T2 vs. T1 | 1.03 (0.65-1.65) | 0.889 |
| T3 vs.T1 | 2.11 (1.40-3.18) | < 0.001 |
| AJCC T staging | ||
| T2 vs. T1 | 1.18 (0.67-2.05) | 0.568 |
| T3 vs. T1 | 1.27 (0.65-2.48) | 0.491 |
| T4 vs. T1 | 2.36 (1.28-4.35) | 0.006 |
| AJCC N staging (N1/2 vs. N0) | 1.61 (1.17-2.22) | 0.004 |
| Portal vein involvement | ||
| Ipsilateral portal vein branch vs. None | 1.04 (0.65-1.66) | 0.865 |
| Bifurcation vs. None | 1.20 (0.59-2.46) | 0.610 |
| Bifurcation plus portal vein branch vs. None | 1.68 (0.82-3.44) | 0.156 |
| With main portal vein encasement vs. None | 7.49 (4.02-13.95) | < 0.001 |
| Hepatic artery invasion | ||
| Branch vs. None | 1.78 (1.15-2.74) | 0.009 |
| Main hepatic artery vs. None | 4.63 (2.03-10.56) | < 0.001 |
| Perineural invasion (Yes vs. No) | 1.09 (0.82-1.44) | 0.571 |
| Liver invasion (Yes vs. No) | 0.85 (0.55-1.33) | 0.477 |
| Spigelian lobe resection (Yes vs. No) | 0.91 (0.68-1.21) | 0.498 |
| Radiotherapy (Yes vs. No) | 1.01 (0.71-1.43) | 0.966 |
| Chemotherapy (Yes vs. No) | 1.08 (0.77-1.52) | 0.662 |
| Surgery treatment outcome | ||
| R1/2 vs. R0 | 1.94 (1.41-2.66) | < 0.001 |
| ECOG status | ||
| I vs. 0 | 2.02 (1.09-3.76) | 0.026 |
| II-III vs. 0 | 2.08 (1.09-3.95) | 0.026 |
| CA19-9 level (U/ml) | ||
| Tertile 2 (73.5-325.0) vs. Tertile 1 (≤ 73.5) | 1.63 (1.14-2.32) | 0.008 |
| Tertile 3 (≥ 325.1) vs. Tertile 1 (≤ 73.5) | 2.39 (1.68-3.41) | < 0.001 |
| Vascular encasement | ||
| Yes vs. No | 1.65 (1.21-2.25) | 0.001 |
| AJCC TNM staging | ||
| II vs. I | 1.18 (0.65-2.16) | 0.586 |
| III vs. I | 1.63 (0.86-3.09) | 0.134 |
| IV vs. I | 2.44 (1.28-4.63) | 0.007 |
| Mayo Clinic | ||
| II vs. I | 1.81 (0.88-3.73) | 0.109 |
| III-IV vs. I | 2.31 (1.12-4.77) | 0.023 |
Abbreviations: 95% CI, 95% confidential interval; AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; MSKCC, Memorial Sloan Kettering Cancer Center.